Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Emergent Biosolutions stock

Learn how to easily invest in Emergent Biosolutions stock.

Emergent Biosolutions Inc is a drug manufacturers-specialty & generic business based in the US. Emergent Biosolutions shares (EBS) are listed on the NYSE and all prices are listed in US Dollars. Emergent Biosolutions employs 2,416 staff and has a trailing 12-month revenue of around $1.6 billion.

How to buy shares in Emergent Biosolutions

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EBS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Emergent Biosolutions stock price (NYSE: EBS)

Use our graph to track the performance of EBS stocks over time.

Emergent Biosolutions shares at a glance

Information last updated 2022-09-26.
Latest market close$20.99
52-week range$20.34 - $55.35
50-day moving average $27.76
200-day moving average $36.33
Wall St. target price$41.07
PE ratio 12.3432
Dividend yield $0 (0%)
Earnings per share (TTM) $1.69

Buy Emergent Biosolutions shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Emergent Biosolutions stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Emergent Biosolutions price performance over time

Historical closes compared with the close of $20.99 from 2022-09-30

1 week (2022-09-23) 0.62%
1 month (2022-09-02) -8.78%
3 months (2022-07-01) -34.06%
6 months (2022-04-01) -51.89%
1 year (2021-09-28) -60.51%
2 years (2020-10-02) -79.07%
3 years (2019-10-02) 52.8
5 years (2017-10-02) 41.31

Is Emergent Biosolutions stock undervalued or overvalued?

Valuing Emergent Biosolutions stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Emergent Biosolutions's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Emergent Biosolutions's P/E ratio

Emergent Biosolutions's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Emergent Biosolutions shares trade at around 12x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Emergent Biosolutions's PEG ratio

Emergent Biosolutions's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.55. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Emergent Biosolutions's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Emergent Biosolutions's EBITDA

Emergent Biosolutions's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $340.7 million.

The EBITDA is a measure of a Emergent Biosolutions's overall financial performance and is widely used to measure a its profitability.

Emergent Biosolutions financials

Revenue TTM $1.6 billion
Operating margin TTM 13.84%
Gross profit TTM $804.1 million
Return on assets TTM 4.9%
Return on equity TTM 6.31%
Profit margin 6.02%
Book value $30.33
Market capitalisation $1 billion

TTM: trailing 12 months

Emergent Biosolutions share dividends

We're not expecting Emergent Biosolutions to pay a dividend over the next 12 months.

Emergent Biosolutions share price volatility

Over the last 12 months, Emergent Biosolutions's shares have ranged in value from as little as $20.34 up to $55.35. A popular way to gauge a stock's volatility is its "beta".

EBS.US volatility(beta: 1.07)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Emergent Biosolutions's is 1.0667. This would suggest that Emergent Biosolutions's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Emergent Biosolutions overview

Emergent BioSolutions Inc. , a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services.

Frequently asked questions

What percentage of Emergent Biosolutions is owned by insiders or institutions?
Currently 10.179% of Emergent Biosolutions shares are held by insiders and 86.094% by institutions.
How many people work for Emergent Biosolutions?
Latest data suggests 2,416 work at Emergent Biosolutions.
When does the fiscal year end for Emergent Biosolutions?
Emergent Biosolutions's fiscal year ends in December.
Where is Emergent Biosolutions based?
Emergent Biosolutions's address is: 400 Professional Drive, Gaithersburg, MD, United States, 20879
What is Emergent Biosolutions's ISIN number?
Emergent Biosolutions's international securities identification number is: US29089Q1058
What is Emergent Biosolutions's CUSIP number?
Emergent Biosolutions's Committee on Uniform Securities Identification Procedures number is: 29089Q105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site